To share a link to this page with a friend, colleague, or family member, please complete the form below:
E-mail addresses entered on this page will be used solely for the purpose of sending an e-card. Endo Pharmaceuticals and companies working with Endo Pharmaceuticals will not share your personal and medical information with any third parties, such as outside mailing lists. To remove yourself from future contact from Endo Pharmaceuticals, e-mail the .
Privacy/Legal
Please complete both e-mail fields with valid addresses.
E-mail addresses entered on this page will be used solely for the purpose of sending an e-card. Endo Pharmaceuticals and companies working with Endo Pharmaceuticals will not share your personal and medical information with any third parties, such as outside mailing lists. To remove yourself from future contact from Endo Pharmaceuticals, e-mail the .
Privacy/Legal
Thank you for sending an e-card about OPANA.com. Your e-card has been sent and the recipient(s) should receive an e-mail notification shortly.
Close
Close
Immediate release for rapid absorption
A lipophilic molecule with rapid absorption1
Randomized, 3-period, crossover study involving 23 volunteers to evaluate the pharmacokinetics and dose proportionality of OPANA. The three 8-day administration periods were separated by a 7-day washout.2
- Linear pharmacokinetics and dose proportionality after single doses and at steady state2*
- No known CYP450 PK drug-drug interactions at clinically relevant doses3
Long 7- to 9-hour half-life2
* The correlation of pharmacokinetics to clinical effects has not been established.
Switching from immediate-release OPANA to extended-release
OPANA ER is a straightforward 1:1 conversion
References
- Data on file, DOF-OP-02, Endo Pharmaceuticals. Chadds Ford, Pa.
- Adams M, Ahdieh H. Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. Drugs R D. 2005;6(2):91-99.
- OPANA Full Prescribing Information. Chadds Ford, Pa: Endo Pharmaceuticals; 2006.